Is there a GT20029 update? I’d have thought Kintor would release bad news of KX-826 with good news of GT20029. Research/Science 3/19/2024
The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.
View this post in the Community →
Similar Community Posts Join
5 / 352 resultscommunity Eliminating scalp itch leads to regrowth (and my RU58841 progress)
User experienced hair regrowth after eliminating scalp itch with RU58841. Others discussed itch and hair loss connection, and effectiveness of combining RU58841 with 5AR inhibitors.
community Switch from fin to dut and its worse
Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.
community Anageninc no longer sell KX-826 (Pyrilutamide) due to receiving a cease and desist letter from Kintor :(
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
community Dutasteride 1 year regression. Depressing. (With pictures for proof)
A user shared their experience of hair loss progression after one year on dutasteride, expressing disappointment with no improvement and considering other treatments like RU58841. Other users offered mixed responses, some seeing no change, others suggesting the hair loss might have been worse without treatment, and discussing the role of testosterone and DHT in hair loss.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
Related Research
6 / 11 results
research The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research What's New in Therapy for Male Androgenetic Alopecia?
research Methodological Considerations in Evaluating Early Clinical Outcomes of GT20029 for Androgenetic Alopecia
GT20029 showed some hair growth improvement, but longer studies are needed for better results.
research Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
GT20029 helps regrow hair in men with hair loss and is well-tolerated.
research Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Topical GT20029 effectively promotes hair regrowth and is well-tolerated for treating androgenetic alopecia.